Financial Performance - For the fiscal year ending December 31, 2023, the company reported a revenue of RMB 397,998,000, a decrease of 1.8% compared to RMB 403,729,000 in 2022[9] - The gross profit for 2023 was RMB 21,366,000, representing a gross margin of 5.37%, up from 3.67% in 2022[5] - The net loss attributable to shareholders for 2023 was RMB 20,160,000, an improvement from a loss of RMB 27,452,000 in 2022[5] - The company reported a basic and diluted loss per share of RMB 1.06 for 2023, compared to RMB 1.45 in 2022[9] - The company reported a total comprehensive loss of RMB 20,159,658 for the year ended December 31, 2023, compared to a loss of RMB 27,451,531 in 2022, indicating an improvement of about 26.5%[13] - The company reported a pre-tax loss of RMB 17,614,179 for the year 2023, compared to a loss of RMB 26,495,118 in 2022[32] - The company reported a loss before tax of RMB (5,601,754) in 2023, compared to a loss of RMB (2,439,963) in 2022, marking a 129.5% increase in losses[47] - The loss attributable to owners for the year was RMB 20,159,658, an improvement from RMB 27,451,531 in the previous year, with a loss per share of RMB 1.06 compared to RMB 1.45[99] Assets and Liabilities - Total assets decreased to RMB 303,278,000 in 2023 from RMB 337,196,000 in 2022[5] - Total liabilities were RMB 238,699,000 in 2023, down from RMB 256,046,000 in 2022[5] - Non-current liabilities decreased from RMB 37,797,202 in 2022 to RMB 21,856,336 in 2023, representing a reduction of approximately 42.2%[11] - Net assets decreased from RMB 81,149,764 in 2022 to RMB 64,579,485 in 2023, a decline of about 20.3%[11] - Total equity attributable to owners decreased from RMB 70,110,966 in 2022 to RMB 49,951,308 in 2023, reflecting a decrease of approximately 28.8%[13] - Total assets as of December 31, 2023, were RMB 303,277,966, down from RMB 337,196,239 in 2022, a decrease of 10.1%[37] - Total liabilities decreased to RMB 238,698,481 in 2023 from RMB 256,046,475 in 2022, a decline of 6.7%[37] Revenue Breakdown - Revenue from fertilizer products was RMB 397,424,063 in 2023, down from RMB 403,176,000 in 2022, reflecting a decline of 1.9%[25] - The segment for elderly care and health services generated revenue of RMB 574,034 in 2023, up from RMB 552,831 in 2022, an increase of 3.8%[25] - The revenue from the sale of general fertilizers in 2023 was RMB 378,821,948, slightly down from RMB 382,401,474 in 2022[41] - For the year ended December 31, 2023, the total revenue from the Chinese market was RMB 406,584,710, a decrease of 9.6% compared to RMB 449,675,951 in 2022[41] Cost Management and Expenses - The company continues to focus on cost management strategies to improve profitability in the upcoming fiscal year[9] - Research and development expenses for 2023 amounted to RMB 2,490,023, an increase from RMB 1,136,489 in 2022, reflecting a significant investment in innovation[39] - Sales and distribution costs decreased by 22.96% to RMB 8,101,974, down from RMB 10,516,917 in the previous year, primarily due to changes in the sales structure of compound fertilizer products[93] - Administrative expenses decreased by 3.93% to RMB 21,803,601 from RMB 22,695,980 in the previous year, attributed to cost-saving measures[95] - Financing costs decreased by 19.19% to RMB 5,172,914 from RMB 6,401,355 in the previous year, due to lower bank loan interest rates[97] Inventory and Receivables - Inventory increased to RMB 90,456,000 in 2023 from RMB 74,004,000 in 2022, indicating a rise in stock levels[10] - Trade receivables decreased significantly to RMB 8,776,000 in 2023 from RMB 31,866,000 in 2022, reflecting improved collection efforts[10] - Accounts receivable decreased significantly to RMB 8,776,649 in 2023 from RMB 31,866,638 in 2022[25] - Total accounts receivable as of December 31, 2023, amounted to RMB 102,165,062, compared to RMB 126,318,040 in 2022, indicating a reduction in receivables[71] Strategic Initiatives - The company has plans for market expansion and new product development, although specific details were not disclosed in the earnings call[9] - The company plans to continue focusing on the delivery of biological compound fertilizers, with expected revenue recognition from contract liabilities in the next 12 months[26] - The company is actively considering fundraising activities, including rights issues and public offerings, to raise new capital[87] - The company has been developing elderly health resource allocation services, including the rental of assistive devices and the sale of elderly health products[90] - The company aims to expand its elderly health product offerings, including rental of assistive devices and sales of elderly food products, to create a new profit growth point[119] Market Conditions - The fertilizer business faced significant price declines in coal, nitrogen, phosphorus, and potassium products in the first half of 2023, leading to cautious inventory management by downstream distributors[88] - The company has strengthened market sales management and adjusted product structures in response to market demand, ensuring stable progress in the compound fertilizer business[88] Governance and Compliance - The company has not applied new accounting standards that have been issued but are not yet effective, indicating a cautious approach to upcoming regulatory changes[23] - The company has not entered into any management contracts for overall business or any major business operations during the year[127] - The audit committee held five meetings during the fiscal year to review the company's audited annual results[135] - The company has complied with all provisions of the Corporate Governance Code, except for one specific provision during the review year[137] Future Outlook - The company reported a significant increase in revenue, with a year-over-year growth of 25% in Q1 2024[140] - The company projects a revenue guidance of $200 million for Q2 2024, reflecting a 20% growth from Q1 2024[140] - New product launches are expected to contribute an additional $50 million in revenue by the end of 2024[140] - Market expansion plans include entering two new international markets by Q3 2024, targeting a 10% increase in overall market share[140]

Financial Performance - For the nine months ended September 30, 2023, the group achieved a total revenue of RMB 305,231,488, representing a year-on-year increase of 0.08% compared to RMB 304,972,430 for the same period in 2022[3] - The gross profit for the nine months ended September 30, 2023, was RMB 11,500,176, reflecting a year-on-year growth of 2.79% from RMB 11,188,179 in 2022[3] - The loss attributable to equity holders for the nine months ended September 30, 2023, was RMB 17,294,189, an improvement from a loss of RMB 21,627,090 in the same period of 2022[4] - The basic loss per share for the nine months ended September 30, 2023, was RMB 0.913, compared to a loss of RMB 1.142 per share for the same period in 2022[4] - The group reported a pre-tax loss of RMB 20,003,700 for the nine months ended September 30, 2023, compared to a pre-tax loss of RMB 21,852,487 in 2022[10] Revenue Breakdown - Revenue from fertilizer products for the nine months ended September 30, 2023, was RMB 296,564,295, down from RMB 303,458,927 in 2022[6] - Revenue from elderly care and health services for the nine months ended September 30, 2023, increased to RMB 8,667,193 from RMB 1,513,503 in 2022[6] - For the nine months ended September 30, 2023, the company reported a total operating revenue of RMB 305,231,488, a year-on-year increase of 0.08% compared to RMB 304,972,430 for the same period in 2022[15] Cost Management - Sales and distribution costs decreased by 25.74% to RMB 6,956,908 from RMB 9,368,063 in the previous year[15] - Research and administrative expenses were reduced by 4.17% to RMB 21,541,186 compared to RMB 22,477,429 in the previous year[15] - The group incurred financing costs of RMB 2,538,214 for the nine months ended September 30, 2023, down from RMB 4,100,365 in 2022[4] - Financing costs decreased significantly by 38.10% to RMB 2,538,214 from RMB 4,100,365 in the previous year[15] Dividend and Shareholder Information - The group did not recommend the payment of dividends for the nine months ended September 30, 2023[4] - The company does not recommend the payment of an interim dividend for the nine months ended September 30, 2023[12] - As of September 30, 2023, the company has 300,000,000 shares held by both Ms. Sun Li and Mr. He Xin, representing 15.83% of the issued share capital each[22] - Major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. with 182,500,000 shares (9.63%), Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%), and Guangdong Jiamei Ecological Technology Co., Ltd. with 180,000,000 shares (9.50%) as of September 30, 2023[26] Corporate Governance - The company has complied with all provisions of the Corporate Governance Code, except for the separation of the roles of Chairman and CEO as required by the code[33] - The company has not approved any new share option schemes during the period ending September 30, 2023[30] - No shares were repurchased, purchased, or sold by the company or its subsidiaries during the review period[32] Strategic Plans - The company plans to enhance market management and adjust product structure to improve market share in the compound fertilizer industry[20]

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二三年第三季度業績公告 GEM GEM 香港聯合交易所有限公司（「聯交所」） （「 」）的特色 GEM 的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公告的資料乃遵照聯交所 證券上市規則（「 上市規則」）而刊載，旨在提供有關天津 泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本公 ...

Financial Performance - For the six months ended June 30, 2023, the group achieved a total revenue of RMB 185,915,928, a decrease of 9.40% compared to RMB 205,210,475 for the same period in 2022[4] - The gross profit for the same period was RMB 6,848,825, representing a decline of 33.96% from RMB 10,370,957 in the previous year[4] - The loss attributable to equity holders of the company was RMB 11,250,040, an improvement from a loss of RMB 13,248,062 in the prior year[4] - The basic loss per share for the period was RMB 0.594, compared to RMB 0.699 for the same period last year[4] - The company's comprehensive gross profit for the same period was RMB 6,848,825, a year-on-year decrease of 33.96% from RMB 10,370,957 in 2022, resulting in a gross profit margin of 3.68% compared to 5.05% in the previous year[32] Assets and Liabilities - The total assets as of June 30, 2023, amounted to RMB 326,577,334, down from RMB 337,196,239 at the end of 2022[6] - Current liabilities totaled RMB 221,585,923, compared to RMB 218,249,273 at the end of 2022, indicating a slight increase[7] - The net asset value of the company was RMB 69,757,798, a decrease from RMB 83,713,353 at the end of the previous year[7] - The net receivables from trade accounts as of June 30, 2023, were RMB 20,359,441, down from RMB 31,866,638 as of December 31, 2022, reflecting a decrease of 36.1%[19] - The company's prepayments and other receivables totaled RMB 61,312,181 as of June 30, 2023, down from RMB 77,654,553 as of December 31, 2022, a decrease of 21.1%[20] - The group's debt-to-asset ratio was 0.79 as of June 30, 2023, compared to 0.75 as of December 31, 2022[38] Cash Flow and Investments - Operating cash flow for the six months ended June 30, 2023, was RMB 3,102,287, compared to a cash outflow of RMB 18,428,270 in the same period of 2022[6] - The net cash used in investing activities for the six months ended June 30, 2023, was RMB 1,288,270, compared to RMB 3,198,037 in the same period of 2022, indicating a decrease of 59.7%[6] - The company invested approximately RMB 461,949 in property, plant, and equipment during the period, significantly lower than RMB 1,428,453 in the same period of 2022[17] Expenses - Research and development expenses for the period were RMB 13,773,232, compared to RMB 12,242,150 in the previous year, indicating increased investment in R&D[5] - The company's income tax expense for the six months ended June 30, 2023, was RMB -41,394, compared to RMB 146,275 in the same period of 2022, indicating a reduction in tax liability[14] - The group's sales and distribution costs for the six months ended June 30, 2023, were RMB 5,277,328, a decrease of 35.00% compared to RMB 8,118,740 for the same period in 2022[33] - Research and administrative expenses increased by 12.51% to RMB 13,773,232 for the six months ended June 30, 2023, compared to RMB 12,242,150 in the same period of 2022[34] - Financing costs decreased by 54.32% to RMB 1,521,452 for the six months ended June 30, 2023, down from RMB 3,330,598 in the same period of 2022[35] Dividends - The company did not recommend the payment of any dividend for the six months ended June 30, 2023[4] - The company has not proposed an interim dividend for the six months ended June 30, 2023, consistent with no dividend declared for the same period in 2022[26] - The company did not declare any interim dividend for the six months ending June 30, 2023[58] Business Operations - The company is involved in two main business areas: bio-composite fertilizers and elderly care services, focusing on the integration of medical and elderly care services[28] - The company has strengthened its market sales management and adjusted product structure in response to market conditions, aiming to stabilize its bio-composite fertilizer business[29] - The company has expanded its elderly health resource allocation business, including the rental of assistive devices and the sale of elderly food products[31] - The aging population in China, with 280 million people aged 60 and above, presents significant opportunities for the elderly care services sector, which the group aims to develop further[43] - The group has developed elderly health resource allocation services, including assistive device rentals and elderly food sales, with plans to expand into more categories[43] Governance and Management - The audit committee reviewed the interim results and report for the six months ending June 30, 2023[52] - No new share option schemes were approved during the first half of 2023[53] - The company did not purchase, sell, or redeem any of its shares during the review period[56] - The company has not entered into any management contracts for its overall business or any major business during the first half of 2023[54] - The board of directors and management are committed to implementing the corporate governance code as per GEM listing rules[57] - There were no reported conflicts of interest or competition with the company's business as of June 30, 2023[50] - The company is currently led by co-CEOs Sun Li and Qin Wenhua, with Sun also serving as the chairperson[57] - The company maintains a focus on transparency and effective internal controls in its governance practices[57] Shareholder Information - As of June 30, 2023, major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. with 182,500,000 shares (9.63%), Xiangyong Investment with 180,000,000 shares (9.50%), and Guangdong Jiamei Ecological Technology Co., Ltd. with 180,000,000 shares (9.50%)[48]

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二三年半年度業績公告 GEM GEM 香港聯合交易所有限公司（「聯交所」） （「 」）的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公告的資料乃遵照聯交所《 證券上市規則》（「 上市規則」）而刊載，旨在提供有關天 津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司的董事願就 ...

Financial Performance - For the three months ended March 31, 2023, the group achieved a total revenue of RMB 86,420,934, a decrease of 3.11% compared to RMB 89,195,530 for the same period last year[3] - The gross profit for the same period was RMB 3,052,579, representing a significant decline of 44.40% from RMB 5,489,781 in the previous year[3] - The loss attributable to equity holders of the company was RMB 5,876,609, slightly improved from a loss of RMB 6,043,544 in the same period last year, resulting in a basic loss per share of RMB 0.310 compared to RMB 0.319[3] - The revenue from fertilizer products was RMB 86,245,207, down from RMB 89,086,907 in the previous year, while revenue from elderly care and health services increased to RMB 175,727 from RMB 108,623[6] - The group reported a pre-tax loss of RMB 7,706,292, compared to a loss of RMB 6,111,450 in the previous year[4] - The income tax expense for the period was RMB 724, compared to zero in the same period last year[8] - The company's gross profit for the same period was RMB 3,052,579, representing a significant decline of 44.40% from RMB 5,489,781 year-on-year, with a gross profit margin of 3.53%, down 2.62% from 6.15% in the previous year[14] Expenses and Costs - The group incurred research and administrative expenses of RMB 6,864,118, compared to RMB 6,621,896 in the previous year[4] - The financing costs for the period were RMB 781,536, an increase from RMB 742,591 in the same period last year[4] Dividends and Shareholder Information - The board of directors did not recommend the payment of dividends for the three months ended March 31, 2023[11] - The weighted average number of ordinary shares for calculating basic loss per share remained constant at 1,894,500,000 shares[10] - As of March 31, 2023, major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., holding 182,500,000 shares (9.63% of issued share capital) and Shenzhen Xiangyong Investment Co., holding 180,000,000 shares (9.50%)[24] - The beneficial ownership structure includes significant stakes held by Xiangyong Investment and Guangdong Jiamei Ecological Technology Co., each holding 180,000,000 shares (9.50%)[24] Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the group's performance for the first quarter ending March 31, 2023[27] - The company has adhered to all provisions of the Corporate Governance Code during the review period[31] - There were no arrangements made that would allow directors or their family members to profit from purchasing company shares during the review period[23] - The company reported no competitive interests from directors, supervisors, or management shareholders during the period ending March 31, 2023[26] Strategic Focus and Future Plans - The company is focusing on the bio-composite fertilizer business and elderly care services, targeting the growing elderly population in China, which reached 280 million (19.8% of the total population) by the end of 2022[19] - The company plans to enhance its marketing management and adjust product structures in response to market demand, aiming to improve market share in the composite fertilizer sector[18] - The company is exploring the development of elderly health resource allocation services, including the rental of assistive devices and sales of elderly food products, to create new profit growth points[19] Capital Structure and Financial Position - The company has not issued new shares during the reporting period, maintaining its existing capital structure[14] - The company did not approve any new share option plans during the period ending March 31, 2023[28] - The company did not repurchase any shares during the review period, nor did it purchase, sell, or redeem any shares[30] - The company has no contingent liabilities related to bank loans as of March 31, 2023, maintaining a stable financial position[15] - The company’s bank borrowings are denominated in RMB and are generally renewed annually upon maturity, indicating a conservative treasury policy[17] Industry Outlook - The composite fertilizer industry is expected to stabilize in terms of raw material prices due to supply-demand dynamics and policy adjustments, following a period of rapid development and subsequent industry adjustments[18]

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二三年第一季度業績公告 GEM GEM 香港聯合交易所有限公司（「聯交所」） （「 」）的特色 GEM 的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公告的資料乃遵照聯交所 證券上市規則（「 上市規則」）而刊載，旨在提供有關天津 泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本公 ...

Financial Performance - The total revenue for the year ended December 31, 2022, was RMB 449.676 million, a decrease of 5.6% compared to RMB 476.385 million in 2021[13]. - The gross profit for the same period was RMB 16.395 million, resulting in a gross margin of 3.65%, down from 9.57% in 2021[13]. - The net loss attributable to shareholders for 2022 was RMB 28.106 million, an improvement from a loss of RMB 42.255 million in 2021[13]. - Total assets as of December 31, 2022, amounted to RMB 337.196 million, a decrease from RMB 347.595 million in 2021[13]. - Total liabilities increased to RMB 253.483 million in 2022, compared to RMB 237.236 million in 2021[13]. - The comprehensive gross profit was RMB 16,395,267, with a gross profit margin of 3.67%, significantly down from 9.57% in the previous year[38]. - Sales and distribution costs decreased by 39.17% to RMB 10,516,917, attributed to adjustments in the business model and reduced marketing expenses[39]. - Administrative expenses were RMB 26,971,894, a reduction of 14.28% from RMB 31,466,638 in the previous year, mainly due to decreased depreciation and bad debt losses[42]. - Research and development expenses dropped by 67.52% to RMB 1,136,489, primarily due to changes in the operating model of a subsidiary[43]. - Financing costs increased by 17.09% to RMB 6,401,517, driven by an increase in short-term borrowings to RMB 56,700,000 from RMB 47,400,000 in the previous year[44]. - The net loss attributable to owners for the year was RMB 28,106,065, with a loss per share of RMB 1.48, compared to RMB 42,255,043 and RMB 2.23 per share in 2021[45]. Business Operations - The company operates in two main business areas: bio-composite fertilizers and elderly care services, indicating a diversified business model[6]. - The company has been focusing on the development of new products in the bio-composite fertilizer sector to enhance market competitiveness[6]. - The company plans to expand its elderly care services across the country, indicating a strategic growth initiative[6]. - The company acquired Shanghai Weidi Network Technology Co., Ltd., which has developed a Direct to Consumer (DTC) system platform, facilitating future online sales of health products and compound fertilizers[26]. - The company plans to expand its elderly health resource allocation business, including the sale of elderly food and health products, aiming to develop this segment into a profit growth point[30]. - The company will enhance market marketing management and adjust product structures based on market demand to improve market share[29]. - The company has strengthened safety and epidemic prevention measures in its elderly care services, ensuring stable operations during the COVID-19 pandemic[25]. - The company aims to transition some offline sales of health products and compound fertilizers to the DTC online platform as it matures[30]. - The company plans to enhance market management and adjust product structure based on market demand to increase market share in the compound fertilizer industry[67]. - The company will continue to expand its elderly health product offerings, including rental aids and elderly food sales, to create a new profit growth point[68]. Market Trends and Challenges - In the first half of 2022, the prices of raw materials for compound fertilizers continued to rise significantly due to global inflation and the Russia-Ukraine conflict, impacting production costs[22]. - The compound fertilizer industry is entering a transformation phase, with companies adjusting product structures to seek upgrades and higher competitive stages[29]. - The aging population in China reached 280 million, accounting for 19.8% of the total population, highlighting the potential growth in the elderly care service industry[68]. - The company is developing a Direct to Consumer (DTC) system platform to transition some elderly health products and compound fertilizers to online sales[68]. Corporate Governance - The company is committed to ensuring the accuracy and completeness of its financial reporting, as stated by its board of directors[1]. - The board consists of 2 executive directors, 3 non-executive directors, and 3 independent non-executive directors, with a total of 9 members as per the company's articles of association[135]. - The audit committee held five meetings during the fiscal year and reviewed the financial performance for the year ending December 31, 2022[126]. - The company has implemented a comprehensive risk management and internal control system to ensure compliance with applicable laws and regulations[140]. - The company has arranged professional training for all directors and senior management regarding the GEM listing rules to mitigate legal risks[143]. - The independent non-executive directors have confirmed their independence according to GEM listing rules, ensuring compliance with governance standards[142]. - The company is committed to maintaining transparency and effective communication with shareholders, ensuring their opinions are conveyed to the board[136]. Environmental and Social Responsibility - The company is committed to sustainable development and has adopted policies to promote social and environmental sustainability[27]. - The group focuses on environmental protection and has implemented clean production practices[180]. - The group ensures that all solid waste is comprehensively utilized and treated according to regulations[183]. - The group adheres to national environmental standards for air, water, and noise pollution[184]. - The company has established a corporate social responsibility strategy centered on caring for employees, the environment, and society[179]. - The company has implemented a clean production audit since 2012, promoting energy saving and pollution reduction among employees[187]. Shareholder Information - The company issued a total of 199,500,000 new shares at a subscription price of HKD 0.25 per share, raising a net amount of HKD 49,225,000 for operational funding in elderly care services[50]. - Major shareholders include State-owned Assets Management with 182,500,000 shares (9.63%), Xiangyong Investment with 180,000,000 shares (9.50%), and Guangdong Jiamei with 180,000,000 shares (9.50%) as of December 31, 2022[119]. - The company did not repurchase any shares during the fiscal year ending December 31, 2022[124]. - No new share option plans were approved during the fiscal year ending December 31, 2022[125]. - Shareholders holding at least 10% of the issued share capital can request a special general meeting[172]. - Shareholders with at least 5% of the issued shares can propose new resolutions for discussion at the annual general meeting[174].

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二二年度全年業績公佈 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公佈的資料乃遵照聯交所 證券上市規則（「 上市規則」）而刊載，旨在提供有關天津 泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本公佈的資料共同及個 別 ...

Financial Performance - For the nine months ended September 30, 2022, the group achieved a consolidated revenue of RMB 304,972,430, a decrease of 14.61% compared to RMB 357,140,151 for the same period last year[6] - The consolidated gross profit for the nine months ended September 30, 2022, was RMB 11,188,179, representing a significant decrease of 71.03% from RMB 38,625,967 in the previous year[6] - The loss attributable to equity holders for the nine months ended September 30, 2022, was RMB 21,627,090, compared to a profit of RMB 1,823,539 for the same period last year, resulting in a loss per share of RMB 1.142[6] - Revenue from fertilizer products and elderly care services for the nine months ended September 30, 2022, was RMB 304,972,430, down from RMB 357,140,151 in the previous year[9] - The group reported a pre-tax loss of RMB 21,852,487 for the nine months ended September 30, 2022, compared to a profit of RMB 1,993,104 in the previous year[7] - The total operating expenses and net losses for the nine months ended September 30, 2022, were RMB 2,905,191, compared to RMB 595,667 in the same period last year[7] - The comprehensive gross profit for the same period was RMB 11,188,179, reflecting a significant decrease of 71.03% from RMB 38,625,967 in 2021[31] - The operating comprehensive gross profit margin was 3.67%, down 7.15% from 10.82% in the previous year[31] - The sales and distribution costs decreased by 45.01% to RMB 9,368,063 from RMB 17,036,248 in 2021[31] - Research and administrative expenses increased by 19.72% to RMB 22,477,429 compared to RMB 18,774,490 in the previous year[31] - Financing costs surged by 189.21% to RMB 4,100,365 from RMB 1,417,792 in 2021[31] - Basic loss per share was RMB 1.142, while the previous year reported earnings per share of RMB 0.096[15] Corporate Governance - The board of directors does not recommend the payment of any dividend for the nine months ended September 30, 2022[6] - The company has not reported any new product developments or market expansion strategies during this period[6] - The company appointed Mr. Qin Wenhua as Co-CEO on September 6, 2022, with Ms. Sun Li transitioning from CEO to Co-CEO[45] - No competition or potential conflicts of interest were reported among the company's directors, supervisors, or management shareholders as of September 30, 2022[46] - The audit committee consists of three independent non-executive directors, with Mr. Li Xudong serving as the chairman due to his professional accounting qualifications and auditing experience[47] - No new share option plans were approved during the period ending September 30, 2022[48] - The company did not enter into any management contracts for overall business or any major business during the period ending September 30, 2022[49] - The board of directors believes that the company has complied with all provisions of the corporate governance code, except for the requirement that the roles of chairman and CEO should be separate[50] - Ms. Sun Li was appointed as co-CEO, while Mr. Qin Wenhua was also appointed as co-CEO, maintaining continuity and stability in company policies[50] - The company aims to enhance corporate governance transparency and independence in the near future[50] Market and Industry Insights - The aging population in China, with 264 million people aged 60 and above, presents significant growth potential for the elderly care services industry[36] - The company plans to enhance marketing management and adjust product structure to improve market share in the compound fertilizer sector[35] Shareholder Information - As of September 30, 2022, the company has a total of 300,000,000 shares held by each of the directors, accounting for 15.83% of the issued shares[37] - Major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. with 182,500,000 shares (9.63%) and Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%) as of September 30, 2022[41] - The company has not achieved the profit guarantee for SJKGC for the fiscal years 2017, 2018, and 2019, with net profits of approximately $2,922,000, $305,000, and $411,000 respectively, all below the guaranteed amount of $5,390,000[44][45] Reporting and Availability - The report will be available for at least seven days on the GEM website and the company's website[51]